Regulatory Blog

As the Swiss life sciences sector grows increasingly global and collaborative, Switzerland’s regulatory authority, Swissmedic , continues...

In an era of data-driven drug development, the European Medicines Agency (EMA) has launched a transformative regulatory framework : the...

Myelodysplastic syndromes (MDS) are a group of complex, clonal blood disorders that predominantly affect older adults and may progress to...

The regulatory landscape for medical devices and digital health technologies in the UK is evolving rapidly, reflecting the growing...

Aluminum contamination in parenteral nutrition (PN) has long posed a silent but serious risk—especially to vulnerable populations like...

In an era where data drives decisions and innovation defines progress, the European Medicines Agency (EMA) and Heads of Medicines...